🚨Results of the #ITECH RCT in Malaysia 🇲🇾 are in & it’s yet another NEGATIVE result for ivermectin:
-n=500 high risk outpatients w/COVID randomized to 0.4 mg/kg IVM x5 days vs SOC
-no difference in rate of progression or time to recovery
-3x more adverse events w/ ivermectin
1/
-n=500 high risk outpatients w/COVID randomized to 0.4 mg/kg IVM x5 days vs SOC
-no difference in rate of progression or time to recovery
-3x more adverse events w/ ivermectin
1/
https://twitter.com/khairykj/status/1455834757867048961
I-TECH was an open label RCT of IVM (0.4 mg/kgx5 days) vs standard of care (SOC)
It enrolled high risk outpatients (>50 yo w/ ≥ 1 comorbidity) w/in 7 days of COVID symptoms
In summary, HIGH risk pts given HIGH dose IVM EARLY & adequately powered 🤔
clinicaltrials.gov/ct2/show/NCT04…
2/
It enrolled high risk outpatients (>50 yo w/ ≥ 1 comorbidity) w/in 7 days of COVID symptoms
In summary, HIGH risk pts given HIGH dose IVM EARLY & adequately powered 🤔
clinicaltrials.gov/ct2/show/NCT04…
2/
We don’t have the full results yet but based on the 🇲🇾 Ministry of Health data this was a NEGATIVE trial.
- IVM recipients did numerically worse: 21.2% progressed to severe disease vs 17.9% receiving SOC (OR 1.29 CI 0.8-2.0)
- time to progression was similar: 2.9 vs 3 days
3/
- IVM recipients did numerically worse: 21.2% progressed to severe disease vs 17.9% receiving SOC (OR 1.29 CI 0.8-2.0)
- time to progression was similar: 2.9 vs 3 days
3/
We have *even less* data on secondary endpoints (the trial has 12 of them) but the one that ICR has shared is worrisome:
- 3x higher adverse events in the ivermectin arm, most commonly diarrhea
(Side note: great use of graphics in the visual abstract 👏🏻)
4/
- 3x higher adverse events in the ivermectin arm, most commonly diarrhea
(Side note: great use of graphics in the visual abstract 👏🏻)
4/
Bottom line:
- #ITECH was a large/adequately power RCT of high dose IVM, given early to high risk outpatients (pretty much exactly what the IVM stans have been clamoring for)
- it found absolutely no benefit to ivermectin in COVID19 in terms of preventing disease progression
5/
- #ITECH was a large/adequately power RCT of high dose IVM, given early to high risk outpatients (pretty much exactly what the IVM stans have been clamoring for)
- it found absolutely no benefit to ivermectin in COVID19 in terms of preventing disease progression
5/
Now I'm sure that the #CultOfIvermectin will invent some reasons to discount this study.
ITECH is conspicuously absent from ivnmeta and other "realtime" websites. But don't worry, I'm sure those anom stats hacks will find a secondary endpoint to fixate on & call it a win.
6/
ITECH is conspicuously absent from ivnmeta and other "realtime" websites. But don't worry, I'm sure those anom stats hacks will find a secondary endpoint to fixate on & call it a win.
6/
For anyone looking objectively:
-multiple large RCTs (EPIC, IVERCORCOVID, TOGETHER, & now ITECH) have found no benefit to IVM
-literally *every* study that found a mortality benefit (Elegazzar, Niaee, etc) has been exposed as fraud
-it doesn't look good for IVM as COVID cure
7/7
-multiple large RCTs (EPIC, IVERCORCOVID, TOGETHER, & now ITECH) have found no benefit to IVM
-literally *every* study that found a mortality benefit (Elegazzar, Niaee, etc) has been exposed as fraud
-it doesn't look good for IVM as COVID cure
7/7
Here’s an even crazier & desperate rationalization 👇
https://twitter.com/nickmmark/status/1456010797495164933
• • •
Missing some Tweet in this thread? You can try to
force a refresh
